Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

Andrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Carlo De Conciliis, Antonio Giordano Resti, Benedetta Mazzi, Antonia Anna Lettini, Judit Demeter, Stefania Dell'Oro, Claudio Doglioni, Eugenio Villa, Mauro Boiocchi, Riccardo Dolcetti

Research output: Contribution to journalArticlepeer-review


Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (<50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.

Original languageEnglish
Pages (from-to)5067-5073
Number of pages7
JournalJournal of Clinical Oncology
Issue number22
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy'. Together they form a unique fingerprint.

Cite this